Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Hradilova, Nada ^a,b   Sadilkova, Lenka ^a   Palata, Ondrej ^a,b   Mysikova, Dagmar ^b   Mrazkova, Hana ^b   Lischke, Robert ^b   Spisek, Radek ^a,b   Adkins, Irena ^a,b  

^a Sotio   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOPOLYSACCHARIDE; POLYINOSINIC POLYCYTIDYLIC ACID; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; CANCER VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG STABILITY; HIGH HYDROSTATIC PRESSURE; HUMAN; HUMAN CELL; HYDROSTATIC PRESSURE; IMMUNOGENICITY; MONOCYTE; NEUTROPHIL CHEMOTAXIS; NON SMALL CELL LUNG CANCER; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; PROCEDURES; TUMOR CELL LINE;

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; HYDROSTATIC PRESSURE; IMMUNOTHERAPY; INTERFERON-GAMMA; LUNG NEOPLASMS;

EID: 85012123599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0171539     Document Type: Article

References (45)

1. Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung cancer. 2011; 73(1):11-7. doi: 10.1016/j. lungcan.2011.02.023 PMID: 21474197
2. Skachkova OV, Khranovska NM, Gorbach OI, Svergun NM, Sydor RI, Nikulina VV. Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer. Experimental oncology. 2013; 35(2):109-13. PMID: 23828386
3. Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE et al. Optimizing dendritic cell-based approaches for cancer immunotherapy. The Yale journal of biology and medicine. 2014; 87(4):491-518. PMID: 25506283
4. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al. Immunobiology of dendritic cells. Annual review of immunology. 2000; 18:767-811. doi: 10.1146/annurev.immunol.18.1.767 PMID: 10837075
5. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR et al. Induction of antigenspecific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92(17):8078-82. PMID: 7644541
6. Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration- resistant prostate cancer. Cancer immunology, immunotherapy: CII. 2013; 62(1):137-47. doi: 10.1007/s00262-012-1317-2 PMID: 22865266
7. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. International journal of oncology. 2004; 24(4):909-17. PMID: 15010829
8. PerroudMWJr., Honma HN, Barbeiro AS, Gilli SC, Almeida MT, Vassallo J et al. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. Journal of experimental & clinical cancer research: CR. 2011; 30:65.
9. Babatz J, Rollig C, Lobel B, Folprecht G, Haack M, Gunther H et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer immunology, immunotherapy: CII. 2006; 55 (3):268-76. doi: 10.1007/s00262-005-0021-x PMID: 16034561
10. Takahashi H, Okamoto M, Shimodaira S, Tsujitani S, Nagaya M, Ishidao T et al. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced nonsmall cell lung cancers. European journal of cancer. 2013; 49(4):852-9. doi: 10.1016/j.ejca.2012.11. 005 PMID: 23245331
11. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11 (8):3017-24.
12. Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. International journal of molecular medicine. 2003; 12(4):493-502. PMID: 12964025
13. Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer. 2005; 103(4):763-71. doi: 10.1002/cncr.20843 PMID: 15637694
14. Engell-Noerregaard L, Hendel HW, Johannesen HH, Alslev L, Svane IM. FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer immunology, immunotherapy: CII. 2013; 62(1):17-25. doi: 10.1007/s00262-012-1306-5 PMID: 22722450
15. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22(14):2808-15.
16. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigenpulsed immature autologous dendritic cells. Lung cancer. 2007; 57(3):365-72. doi: 10.1016/j.lungcan. 2007.04.002 PMID: 17509725
17. Yannelli JR, Sturgill J, Foody T, Hirschowitz E. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung cancer. 2005; 47(3):337-50. doi: 10.1016/j.lungcan.2004.08.008 PMID: 15713517
18. Hirschowitz EA, Mullins A, Prajapati D, Baeker T, Kloecker G, Foody T et al. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011; 6(1):169-73.
19. Um SJ, Choi YJ, Shin HJ, Son CH, Park YS, Roh MS et al. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung cancer. 2010; 70(2):188-94. doi: 10. 1016/j.lungcan.2010.02.006 PMID: 20223553
20. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annual review of immunology. 2013; 31:51-72. doi: 10.1146/annurev-immunol-032712-100008 PMID: 23157435
21. Adkins I, Fucikova J, Garg AD, Agostinis P, Spisek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology. 2014; 3(12):e968434. doi: 10.4161/21624011. 2014.968434 PMID: 25964865
22. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L et al. Molecular characteristics of immunogenic cancer cell death. Cell death and differentiation. 2008; 15(1):3-12. doi: 10.1038/sj.cdd. 4402269 PMID: 18007663
23. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nature reviews Cancer. 2012; 12(12):860-75. doi: 10.1038/nrc3380 PMID: 23151605
24. Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. International journal of cancer Journal international du cancer. 2014; 135(5):1165-77. doi: 10.1002/ijc.28766 PMID: 24500981
25. Mikyskova R, Stepanek I, Indrova M, Bieblova J, Simova J, Truxova I et al. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. International journal of oncology. 2016; 48(3):953-64. doi: 10.3892/ijo.2015.3314 PMID: 26718011
26. Truxova I, Pokorna K, Kloudova K, Partlova S, Spisek R, Fucikova J. Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs. Immunology letters. 2014; 160(1):39-49. doi: 10.1016/j.imlet.2014.03.010 PMID: 24726860
27. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(22):8055-62.
28. Karanikas V, Tsochas S, Boukas K, Kerenidi T, Nakou M, Dahabreh J et al. Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy. Cancer biology & therapy. 2008; 7(3):345-52.
29. Tajima K, Obata Y, Tamaki H, Yoshida M, Chen YT, Scanlan MJ et al. Expression of cancer/testis (CT) antigens in lung cancer. Lung cancer. 2003; 42(1):23-33. PMID: 14512184
30. Grunwald C, Koslowski M, Arsiray T, Dhaene K, Praet M, Victor A et al. Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. International journal of cancer Journal international du cancer. 2006; 118(10):2522-8. doi: 10.1002/ijc.21669 PMID: 16353146
31. Fucikova J, Rozkova D, Ulcova H, Budinsky V, Sochorova K, Pokorna K et al. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. Journal of translational medicine. 2011; 9:223. doi: 10.1186/1479-5876-9-223 PMID: 22208910
32. West MA, Wallin RP, Matthews SP, Svensson HG, Zaru R, Ljunggren HG et al. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science. 2004; 305(5687):1153-7. doi: 10.1126/science.1099153 PMID: 15326355
33. Macagno A, Napolitani G, Lanzavecchia A, Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends in immunology. 2007; 28(5):227-33. doi: 10.1016/j.it. 2007.03.008 PMID: 17403614
34. Abdi K, Singh NJ, Matzinger P. Lipopolysaccharide-activated dendritic cells: "exhausted" or alert and waiting? Journal of immunology. 2012; 188(12):5981-9.
35. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. The Journal of experimental medicine. 1996; 184(2):747-52. PMID: 8760829
36. Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Seminars in immunology. 2009; 21(5):265-72. doi: 10.1016/j.smim.2009.05.010 PMID: 19524453
37. Rouas R, Lewalle P, El Ouriaghli F, Nowak B, Duvillier H, Martiat P. Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. International immunology. 2004; 16(5):767-73. doi: 10.1093/intimm/dxh077 PMID: 15096480
38. Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. The Journal of experimental medicine. 2003; 198(1):111-22. doi: 10.1084/jem.20021542 PMID: 12835477
39. Alanio C, Lemaitre F, Law HK, Hasan M, Albert ML. Enumeration of human antigen-specific naive CD8 + T cells reveals conserved precursor frequencies. Blood. 2010; 115(18):3718-25. doi: 10.1182/blood- 2009-10-251124 PMID: 20200354
40. Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number? Current opinion in immunology. 2005; 17(3):320-5. doi: 10.1016/j.coi.2005.03.002 PMID: 15886124
41. He XS, Mahmood K, Maecker HT, Holmes TH, Kemble GW, Arvin AM et al. Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses. The Journal of infectious diseases. 2003; 187(7):1075-84. doi: 10.1086/368218 PMID: 12660922
42. Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y et al. First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer science. 2012; 103(1):150-3. doi: 10.1111/j.1349-7006.2011.02106.x PMID: 22221328
43. Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E et al. Vaccine-induced CD4 + T cell responses to MAGE-3 protein in lung cancer patients. Journal of immunology. 2004; 172 (5):3289-96.
44. Brunsvig PF, Kyte JA, Kersten C, Sundstrom S, Moller M, NyakasM et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(21):6847-57.
45. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 2007; 109(12):5346-54. doi: 10.1182/blood-2006-10- 051318 PMID: 17327412